Stemina Biomarker Discovery: devTOX DiscoveryTM and devTOX quickPredictTM [SOT 2013]
Stemina’s CEO, Beth Donley, presented Stemina’s new in vitro assay for prediction of developmental toxicity: devTOX quickPredict.
Stemina’s neurological disorders business unit has developed a test to aid in the earlier diagnosis of autism spectrum disorder.
